Abstract: An external counter pulsation system (ECP) and method for using the system to improve circulation as well as cardiovascular related diseases. The ECP system of the present invention comprises a helical air bladder for modulating blood flow of major veins and arteries of the thigh. High efficiency is realized with the helical shape of the air bladder to lower the cost, weight and size of the ECP of the present invention.
Abstract: Disclosed herein is a CLEC2 fusion protein comprising a first polypeptide and a second polypeptide coupled to the upstream of the first polypeptide. According to embodiments of the present disclosure, the first and the second polypeptides respectively comprise the amino acid sequences of SEQ ID NOs: 1 and 2. Also disclosed therein are uses of the CLEC2 fusion protein in treating severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and treating influenza virus infection.
Abstract: Provided is a method for preventing or treating a metabolic disorder, including administering to a subject a therapeutically effective amount of TRABID protein or a functionally related variant thereof, or a nucleic acid encoding TRABID protein or a functionally related variant thereof. Also provided is a method for reducing fat accumulation through TRABID-induced deubiquitination to promote autophagy activity and lipid metabolism.
Type:
Grant
Filed:
December 2, 2021
Date of Patent:
November 14, 2023
Assignees:
Academia Sinica, National Yang Ming Chiao Tung University
Abstract: This disclosure provides treatment kit that are capable of modulating the immune response. The treatment kit may also be used enhance the immunogenicity of antigens released from cell debris. Also provided are methods of using the treatment kit.
Type:
Grant
Filed:
January 3, 2019
Date of Patent:
November 14, 2023
Assignee:
ACADEMIA SINICA
Inventors:
Che-Ming Jack Hu, Saborni Chattopadhyay
Abstract: Disclosed herein is a method for treating or preventing a coronavirus infection, which comprises administering to a subject in need thereof an effective amount of a composition comprising Flt3 receptor interacting lectin (FRIL) from Lablab purpureus. Also disclosed is a pharmaceutical composition comprising a pharmaceutically acceptable excipient, a Lablab purpureus FRIL, and an additional therapeutic agent.
Abstract: A system and method for image-guided microscopic illumination are provided. A processing module controls an imaging assembly such that a camera acquires an image or images of a sample in multiple fields of view, and the image or images are automatically transmitted to a processing module and processed by the first processing module automatically in real-time based on a predefined criterion so as to determine coordinate information of an interested region in each field of view. The processing module also controls an illuminating assembly to illuminate the interested region of the sample according to the received coordinate information regarding to the interested region, with the illumination patterns changing among the fields of view.
Type:
Grant
Filed:
February 3, 2022
Date of Patent:
October 17, 2023
Assignee:
Academia Sinica
Inventors:
Jung-Chi Liao, Yi-De Chen, Chih-Wei Chang, Weng Man Chong
Abstract: Disclosed herein are recombinant polynucleotide sequences, vectors, host cells and methods for producing astaxanthin. The recombinant polynucleotide sequence is designed to provide a higher level of astaxanthin precursors via a shorter metabolic pathway, and thereby attains higher level of end products (e.g., astaxanthin) with desired stereoisomeric form and/or esterified form.
Abstract: Disclosed herein are novel synthetic polypeptides and uses thereof in the preparation of liposomes. According to embodiments of the present disclosure, the synthetic polypeptide comprises a membrane lytic motif, a masking motif, and a linker configured to link the membrane lytic motif and the masking motif. The linker is cleavable by a stimulus, such as, light, protease, or phosphatase. Once being coupled to a liposome, the exposure to the stimulus cleaves the linker that results in the separation of the masking motif from the membrane lytic motif, which in turn exerts membrane lytic activity on the liposome that leads to the collapse of the intact structure of the liposome, and releases the agent encapsulated in the liposome to the target site. Also disclosed herein are methods of diagnosing or treating a disease in a subject by use of the present liposomes.
Abstract: Compounds for use in prevention and/or treatment of pain are disclosed. The compounds are derived by conjugation of N6-(4-hydroxybenzyl)adenosine and analogous compounds with amino acids or peptides. In one embodiment of the invention, the compound is 5?-O-(glycine-N-carbonyl-N6-(4-hydroxybenzyl)adenosine (I-a1). In another embodiment of the invention, the compound is 5-deoxy-5?-(glycine-N-amido)-N6-(4-hydroxybenzyl)adenosine (I-d1). Also disclosed are methods of making and using the same.
Abstract: The present invention provides a method of improving the ability of plants to resistance diseases, comprising using a strain of Bacillus amyloliquefaciens and a Bidens plant extract; and the Bidens plant extract enhances the ability of the Bacillus amyloliquefaciens to inhibit the growth of the Acidovorax avenae subsp. citrulli, increases the metabolic activity of the Bacillus amyloliquefaciens, increases the amount of the biofilm formation of the Bacillus amyloliquefaciens, and maintains the alive number of the Bacillus amyloliquefaciens.
Type:
Grant
Filed:
December 10, 2019
Date of Patent:
August 29, 2023
Assignees:
NATIONAL TAIWAN UNIVERSITY, ACADEMIA SINICA
Abstract: An acoustic scene conversion method, comprising: receiving sound signals including user's speech and scenic sounds; processing the sound signals according to an artificial intelligence model to generate enhanced speech signals without scenic sounds; and mixing the enhanced speech signals with new scenic sounds to produce converted sound signals.
Type:
Grant
Filed:
June 1, 2021
Date of Patent:
August 29, 2023
Assignee:
ACADEMIA SINICA
Inventors:
Tsao Yu, Syu-Siang Wang, Szu-Wei Fu, Alexander Chao-Fu Kang, Hsin-Min Wang
Abstract: A teicoplanin derivative useful for treating an infectious disease, having the structure of formula (I): or the pharmaceutically acceptable salt, solvate, stereoisomer, derivative or prodrug thereof. In an exemplary compound of formula (I), R1 is R2 is H, R3 is —N(CH3)2, and R4 is H.
Type:
Grant
Filed:
December 31, 2019
Date of Patent:
August 29, 2023
Assignee:
Academia Sinica
Inventors:
Tsung-Lin Li, Chun-Man Huang, Kuan-Hung Lin
Abstract: Disclosed herein is a micro-reactor for synthesizing a molecule, for example, compound, a nanoparticle, or a quantum dot. According to embodiments of the present disclosure, the apparatus comprises a processor, a storage unit, a reaction unit, a detector, and a collector, in which the storage unit and the reaction unit are independently controlled by the process. Optionally, the present micro-reactor further comprises a diagnostic device for performing a diagnostic test on a biological sample by use of the molecule. Also disclosed wherein are methods of diagnosing and treating a disease in a subject with the aid of the present micro-reactor.
Abstract: A method of inhibiting an overactive fibroblast growth factor receptor 3 (FGFR3) in a cell by contacting the cell with a composition that contains an effective amount of Pheophorbide a, Pyropheophorbide a, or an active derivative thereof. Also disclosed is a method for treating a disorder associated with an overactive FGFR3 with a composition containing an effective amount of Pheophorbide a, Pyropheophorbide a, or an active derivative thereof. Further, a composition for treating a disorder associated with an overactive FGFR3 is described. The composition contains an ethanol extract of Amaranthus viridis.
Type:
Application
Filed:
March 3, 2023
Publication date:
August 3, 2023
Applicant:
ACADEMIA SINICA
Inventors:
Yuan-Tsong Chen, Yi-Ching Lee, Jer-Yuarn Wu, Hsiao-Jung Kao
Abstract: The present invention relates to oligonucleotide conjugates and preparation and applications thereof. In particular, the present invention relates to an oligonucleotide conjugated to a biomolecule (e.g. an antibody) and/or an agent of interest (e.g. a drug). In certain embodiments, the oligonucleotide of the present invention is a hybridized complex of a single strand oligonucleotide carrying a biomolecule and a complementary strand oligonucleotide bearing an agent of interest where the hybridized nucleotide segment acts as a linker to link the biomolecule and the agent of interest in one molecule.
Type:
Application
Filed:
April 15, 2021
Publication date:
July 27, 2023
Applicant:
ACADEMIA SINICA
Inventors:
Andrew H.-J. WANG, Cheng-Chung LEE, Nai-Shu HSU, Wen-Chih KUO
Abstract: Disclosed herein are anti-IL-1? antibodies capable of binding to human IL-1? and blocking its biological activities. Also provided herein are pharmaceutical compositions comprising the anti-IL-1? antibodies and therapeutic and diagnostic uses of such antibodies.
Type:
Application
Filed:
June 15, 2021
Publication date:
July 13, 2023
Applicant:
ACADEMIA SINICA
Inventors:
Andrew H.-J. WANG, Wen-Chih KUO, Cheng-Chung LEE, An-Suei YANG
Abstract: Disclosed herein are methods for selecting an antibody fragment specific to an influenza virus. According to certain embodiments of the present disclosure, the influenza virus may be influenza virus type A (IAV) or influenza virus type B (IBV). Also disclosed herein are the selected antibodies, recombinant antibody produced from the selected antibodies, and the uses thereof in the diagnosis of influenza virus infection.
Abstract: Monocyte-specific nucleic acid aptamers and lipid nanoparticles comprising such for use in delivering therapeutic agents or diagnostic agents to cancer sites. Also disclosed herein are use of the aptamer-based lipid nanoparticle drug delivery system for treating or detecting cancer.
Type:
Application
Filed:
May 26, 2021
Publication date:
June 29, 2023
Applicant:
Academia Sinica
Inventors:
PATRICK CH HSIEH, KENGJUNG LEE, HUNG-CHIH CHEN
Abstract: Monocyte-specific nucleic acid aptamers and lipid nanoparticles comprising such for use in drug delivery. Also disclosed herein are use of the aptamer-based lipid nanoparticle drug delivery system for treating heart injury.
Type:
Application
Filed:
May 26, 2021
Publication date:
June 29, 2023
Applicant:
Academia Sinica
Inventors:
PATRICK CH HSIEH, HSIEN-MING LEE, KENG-JUNG LEE, HUNG-CHIH CHEN